Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
Accomplished Industry Veteran Brings Extensive Quality and Regulatory Affairs Experience in Cell and Gene Therapies and Medical Devices
View HTML
Toggle Summary Vericel to Present at the 16th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 16 th
View HTML
Toggle Summary Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association
CAMBRIDGE, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the presentation of Epicel ® (cultured epidermal autografts [CEA])
View HTML
Toggle Summary Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results
Record Revenues of $16.5 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious
View HTML
Toggle Summary Vericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017
CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What:  Vericel Corporation
View HTML
Toggle Summary Vericel to Present at Multiple Upcoming Investor Conferences
  CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the
View HTML
Toggle Summary Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has designated the
View HTML
Toggle Summary Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the first implant of MACI ® (autologous cultured chondrocytes on
View HTML
Toggle Summary Vericel Corporation Announces Exercise of Underwriters' Over-Allotment Option and Closing of $20 Million Offering of Common Stock
  CAMBRIDGE, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation ( VCEL ), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has closed its previously announced underwritten public offering
View HTML
Toggle Summary Vericel Corporation Prices $17 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the pricing of its previously announced underwritten public offering
View HTML